Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus HYDROCHLOROTHIAZIDE W HYDRALAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus HYDROCHLOROTHIAZIDE W HYDRALAZINE.
HYDRO-D vs HYDROCHLOROTHIAZIDE W/ HYDRALAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Hydralazine directly relaxes arteriolar smooth muscle via mechanisms involving nitric oxide, leading to vasodilation.
25-100 mg orally once daily in the morning.
Oral: hydrochlorothiazide 25-50 mg plus hydralazine 25-100 mg, twice daily; maximum hydralazine 300 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment); Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); clinical context: slow acetylators have higher risk of lupus-like reactions.
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Hydrochlorothiazide: ~70% renal (unchanged), 30% metabolized with metabolites excreted renally; Hydralazine: 80-90% renal (metabolites), <10% unchanged, some biliary/fecal.
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic